

Kimberly M. Eads, MSN, BA Th., FNP-BC, CCRP
The Indiana Clinical Trials Center, PC
2155 E. Main Street, Suite 200
Plainfield, Indiana 46168
Phone: (317) 837-6082
Email: keads@indianatrials.com

Education:

Life Christian University, Tampa, FL

- Bachelor of Arts Theology
- Graduated August 2021

Indiana Wesleyan University, Marion

- Masters of Science in Nursing, Family Nurse Practitioner
- Graduated December 13, 2014

Indiana University, Indianapolis

- Bachelor of Science in Nursing
- Graduated: August 2007

Honors and Activities:

- Alpha Delta Pi Sorority, 2003-2004
- Dean's List, 2002, 2004
- Psychology Mentor, 2005

Qualifications and Certifications:

Registered Nursing License:

- License number: 28175559A

Nurse Practitioner License:

- License number: 71005371A, 71005371 B
- NPI number: 1033502794
- DEA number: ME3461035

ANCC Family Nurse Practitioner Board Certification

- January 21, 2015- Current
- Certification number: 2014031848

Certifications:

- Good Clinical Practice Certification- Citi Group (05/2013-current)
- Good Clinical Practice Certification- NIDA (05/2015-current)
- Certified Clinical Research Professional (2012-current)
- PASI/IGA Investigator Certification- (11/2014-Current)
- Acne IGA/ Lesion Counting Investigator Certification- (11/2014- Current)
- Eczema IGA/EASI Investigator Certification- 02/2015- Current
- CPR Certification (11/09/2016-Present)
- IATA Dangerous Goods Certification (05/21/2020- Current)
- Columbia Suicide Severity Rater Training (04/03/2018- Current)

keads
21 MAY 2020

- Botox Injector Certification (05/17/2022)

Professional Experience:

September 2, 2008- Present

Director of Clinical Research and Operations and Sub-Investigator

The Indiana Clinical Trials Center, PC

Responsibilities: Conducting and managing all aspects of the clinical research process and providing specialized care to dermatology patients

January 2016- Present

Program Speaker

Janssen Department of Medical Education

Responsibilities: Presenting informational materials for biologic medications. Speaking to large groups of physician/prescribers/medical assisting personnel. Answering questions regarding drug safety and efficacy. Presenting real patient case studies to relate prescribers to their own patient situations.

February 2011- 2018

Program Speaker

AbbVie- Abbott Park Illinois

Responsibilities: Presenting informational materials for biologic medications. Speaking to large groups of physician/prescribers/medical assisting personnel. Answering questions regarding drug safety and efficacy. Presenting real patient case studies to relate prescribers to their own patient situations.

August 20, 2007- November 22, 2008

Registered Nurse

St. Francis Hospital- Mooresville, Indiana

Mooresville, IN

Responsibilities: Provide specialized care to critically ill and post partum patients

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

Gooderham, Kircik, Zirwas, Mark Lee, Kempers, Draelos, Ferris, Jones T, Saint-Cyr Proulx E, Bissonnette R, Bhatia N, Koppel R, Guenther S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droege M, Berk D. *The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study*. JDD. February 2012.

Blaauvelt A, Farberg A, Sinclair R, Hanna S, Asahina A, Igarashi A, Guenther S, Eads K, et. al. *5-year efficacy of tildrakizumab 100 and 200 mg in achieving and maintaining PASI 75/90/100 and PGA 0/1 in resurface 1 and 2*. Poster Presentation. Winter Clinical Dermatology Conference. Virtual. Jan 16-24, 2021.

Guenther S, McFalda W, Tate M, Eads K, et. al.. *Phase 2 Safety and Efficacy of VP-102, a Drug-Device Combination Product Containing Cantharidin (0.7% w/v), for the treatment of External Genital Warts (Care-1)*.

Blaauvelt A, Sinclair R, Asahina A, Igarashi A, Mendelsohn A, Rozzo S, Eads K, Guenther S, Guenther L. *5-year efficacy of tildrakizumab 100 and 200 mg in achieving and maintaining PASI 75/90/100 and PGA 0/1 in resurface 1 and 2*. Poster Presentation. American Academy of Dermatology. Virtual. Apr 23-25, 2021.

leaf
21 MAY 2020

Bhatia N, Bukhalo M, Guenther S, Eads, K et. al.. *Microneedle lesion preparation prior to aminovulnic acid photodynamic therapy for actinic keratosis on the face*. Poster Presentation. The American Society for Laser Medicine and Surgery. Virtual. May 15-16, 2021.

Zirwas M, Draelos Z, DuBois J, Kircik L, Moore A, Gold L, Alonso -Llamazares J, M. Bukhalo, Bruse S, Eads K, Green L, Guenther S, Ferris L, Forman S, Kempers S, Lain E, Lynde C, Pariser D, D, Toth D, Yamuchi P, Feng A, Higham R, Burnett P, Berk D *A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients with Moderate to Severe Seborrheic Dermatitis*. Poster Presentation 30th Congress of The European Academy of Dermatology and Venerology. Sept 29 – October 2, 2021.

Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris L, Jones T, E, Saint-Cyr Proulx R, Bissonnette R, Bhatia N, Koppel R, Guenther S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droege M, Berk D *The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof-of-concept study*. British Journal of Dermatology.

Teng J, Bunick C, Guenther S, Murrell D, Marathe K, Kempers S, Eads K, Mendelsohn A, Raiz J, Tavakkol A, Castelo-Soccio L *The CONTROL Study: Efficacy and safety of a novel topical isotretinoin formulation (TMB-001) for the treatment of recessive X-linked and autosomal recessive lamellar congenital ichthyosis*. Presented at the 2022 Winter Clinical Dermatology Conference Poster. January 14–19, 2022.

Zirwas M, Draelos Z, DuBois J, Kircik L, Moore A, SteinGold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green L, Guenther S, Ferris L, Forman S, Kempers S, Lain E, Lynde C, Parise D, Toth D, Yamauchi P, Higham R, Feng A, Burnett P, Berk D *Randomized, Double-blind, Vehicle-controlled Phase 2a Study of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis*. Manuscript. March 10, 2022.

Murrell DF, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn AM, Raiz J, Bunick CG *Congenital ichthyosis subtype analysis of primary efficacy of a novel topical isotretinoin formulation (TMB-001): Results from the phase 2b CONTROL study in patients with recessive X-linked and autosomal recessive lamellar congenital ichthyosis*. Annual American Academy of Dermatology. Abstract. March 25–29, 2022.

Teng J, Bunick C, Guenther S, Murrell D, Marathe Kempers S, Eads K, Mendelsohn A, Raiz J, Castelo-Soccio L *The CONTROL study: A randomized, double-blind vehicle-controlled Phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis*. JAAD. Manuscript. April 20, 2022.

Teng J, Castelo-Soccio L, Bunick C, Guenther S, Kempers S, Eads K, Mendelsohn A, Raiz J, Murrell D, Marathe K *Efficacy of topical isotretinoin TMB-001 in children and adults with congenital ichthyosis: Phase 2b CONTROL study results*. The European Academy of Dermatology and Venereology (EADV) 2022 Meeting. Abstract. April 21, 2022

Teng J, Bunick C, Guenther S, Murrell D, Marathe K, Kempers S, Eads K, Mendelsohn A, Raiz J, Castelo-Soccio L *Efficacy and safety of topical isotretinoin (TMB-001) treatment in patients with X-linked recessive or autosomal recessive lamellar congenital ichthyosis: CONTROL study results*. The European Academy of Dermatology and Venereology (EADV) 2022 Meeting. Abstract. April 21, 2022

Marathe K, Teng J, Guenther S, Bunick C, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D *Effect of topical isotretinoin (TMB-001) treatment on laboratory parameters in patients with congenital ichthyosis: CONTROL study results*. The European Academy of Dermatology and Venereology (EADV) 2022 Meeting. Abstract. April 21, 2022.

leaf
21 MAY 2022

Teng J, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Murrell D, Mendelsohn A, Raiz J, Bunick C *Effect of topical isotretinoin formulation (TMB-001) concentration on incidence of local skin reactions in patients with congenital ichthyosis: Phase 2b CONTROL study results*. The European Academy of Dermatology and Venereology (EADV) 2022 Meeting. Abstract. April 21, 2022.

Castelo-Soccio L, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Murrell D, Mendelsohn A, Raiz J, Bunick C *Change in quality-of-life measurements after treatment with topical isotretinoin formulation (TMB-001) at 12 weeks in patients with congenital ichthyosis at baseline: Phase 2b CONTROL study results*. The European Academy of Dermatology and Venereology (EADV) 2022 Meeting. Abstract. April 21, 2022.

Bunick C, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D *Characteristics of patients with congenital ichthyosis achieving greater than 50% reduction in Visual Index for Ichthyosis Severity scaling score relative to baseline after topical isotretinoin formulation TMB-001: CONTROL study results*. The European Academy of Dermatology and Venereology (EADV) 2022 Meeting. Abstract. April 21, 2022.

Murrell D, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C *Congenital ichthyosis subtype analysis of primary efficacy of a novel topical isotretinoin formulation (TMB-001): Results from the Phase 2b CONTROL study in patients with recessive X-linked and autosomal recessive lamellar congenital ichthyosis*. AAD. Abstract. 2022.

Gooderham M, Kircik L, Zirwas M, Lee M, Kempers S, Draelos Z, Ferris L, Jones T, E, Saint-Cyr Proulx R, Bissonnette R, Bhatia N, Koppel R, Guenther S, Eads K, Welgus H, Merritt C, Elias M, Navale L, Higham R, Droegge M, Berk D *The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof-of-concept study*. JAAD. Manuscript. May 4, 2022.

Teng J, Castelo-Soccio L, Bunick C, Guenther S, Kemper S, Eads K, Mendelsohn A, Raiz J, Murrell D, Marathe K *Efficacy of topical isotretinoin TMB-001 in children and adults with congenital ichthyosis: Phase 2b CONTROL study results*. The Society of Pediatric Dermatology (SPD) 2022 Meeting. Poster. June 21, 2022.

Murrell D, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C *Congenital ichthyosis subtype analysis of primary efficacy of a novel topical isotretinoin formulation (TMB-001): Results from the Phase 2b CONTROL study in patients with recessive X-linked and autosomal recessive lamellar congenital ichthyosis*. European Academy of Dermatology and Venereology (EADV) Meeting. Abstract. 2022.

Bunick C, Murrell D, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Mendelsohn A, Raiz J, Castelo-Soccio L *Change in Visual Index for Ichthyosis Severity after treatment with topical isotretinoin formulation TMB-001 in patients with congenital ichthyosis: CONTROL study results*. Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

Marathe K, Murrell D, Teng J, Guenther S, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C *Effect of topical isotretinoin formulation TMB-001 on percent BSA with ichthyosis relative to baseline in patients with congenital ichthyosis: results from the CONTROL study*. Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

Guenther S, Marathe K, Bunick C, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D, Teng J *Improvement in IGA scores following treatment with topical isotretinoin (TMB-001) in patients with congenital ichthyosis: results from the CONTROL study*. Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

Lead
21 MAY 2022

Bunick C, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D *Proportion of patients with an IGA of cleared or almost cleared ichthyosis after treatment with topical isotretinoin formulation TMB-001 at 12 weeks: CONTROL study results.* Canadian Dermatology Association (CDA) Meeting. Poster. 2022.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenther, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis.* Maui Derm NP/PA Fall, 9/29-10/2, 2021, Asheville, NC and virtual. Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenther, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis.* Fall Clinical Derm, 10/21-24, 2021, Las Vegas, NV Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenther, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis.* Derm Update Fall Meeting, Nov 11-13, 2021, Montreal, Canada. Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenther, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis.* Fall Clinical NP/PA, Nov 12-14, 2021, Orlando, FL. Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenther, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis.* Winter Clinical Dermatology Conference, 1/14-19, 2022, Koloa, HI. Poster.

Zirwas, Draelos, DuBois, Kircik, Moore, Stein Gold, Alonso-Llamazates, Bukhalo, Bruce, Eads, Green, Guenther, Ferris, Forman, Kempers, Lain, Lynde, Pariser, Toth, Yamauchi, Feng, Burnett, Higham, Berk A *Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis.* MauiDerm for Dermatologists, 1/24-28, 2022, Maui, HI. Poster.

Murrell D, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Bunick C. *Phase 2B randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis.* JEADV.

Zirwas M, Draelos Z, DuBois, Kircik J, Moore A, Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green L, Guenther S, Ferris L, Forman S, Kempers S, Lain E, Pariser D, Toth D, Yamauchi P, Higham R, Krupa D, Burnett P, Berk D, *Randomized, Double-blind, Vehicle-controlled Phase 2a Study of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis: A Randomized Clinical Trial.* JAMA Dermatology. Manuscript.

*Lead
21 MAY 2022*

Bunick C, Teng J, Guenther S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. *Characteristics and outcomes for participants with congenital ichthyosis. who responded to treatment with the topical isotretinoin formulation TMB-001: Results from the Phase 2b CONTROL study.* CED Manuscript.

Zirwas MJ, Draelos ZD, DuBois J, Guenther S, Eads K. *Efficacy of Roflumilast Foam, 0.3%, in Patients with Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.* JAMA Dermatol. 2023;159(6):613–620. doi:10.1001/jamadermatol.2023.0846

CLINICAL TRIAL EXPERIENCE:

09/2008 - 12/2009	Phase IV Study of Raptiva Safety (RESPONSE)
9/2008 - 10/2008	Phase III Study of Brand vs. Generic Duac Gel Efficacy and Safety
9/2008 - 2/2010	Phase III Study of Raptiva Effectiveness for Scalp Psoriasis
9/2008 - 1/2009	Phase III Study of Brand vs. Generic Aldara Cream for the Treatment of Actinic Keratosis Efficacy and Safety
9/2008 – 04/2013	Phase IV Five Year Study of Enbrel Safety (OBSERVE)
10/2008 - 4/2009	Phase III Study of Ingenol Mebutate Gel vs Placebo for the Treatment of Actinic Keratosis Efficacy and Safety
12/2008 - 6/2009	Phase III Study of ABT-874 vs Etanercept vs Placebo for the Treatment of Moderate to Severe Plaque Psoriasis Efficacy and Safety
12/2008 - 1/2009	Phase III Study of Brand vs Generic Protopic 0.1% for the Treatment of Atopic Dermatitis
12/2008 - 2023	Phase IV Study of Humira Safety for the Treatment of Plaque Psoriasis (ESPRIT Registry)
1/2009 - 06/2012	Phase III Study of Alitretinoin vs Placebo for the Treatment of Chronic Hand Eczema Efficacy and Safety
2/2009 - 9/2009	Phase III Study of Brand vs. Generic Aldara Cream for the Treatment of Actinic Keratosis Efficacy and Safety
5/2009 - 11/2009	Phase IV Study, Open-label, 12-week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction with Oracea (doxycycline, USP) Capsules 40 mg (30mg immediate release and 10 mg delayed release beads) as Monotherapy or as Add-on Therapy to Existing Topical Regimens for the Treatment of Rosacea
5/2009 - 02/2012	A Phase III, Multi-Center, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Study with ABT-874
6/2009 - 1/2010	A Phase III, Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle Controlled Study to evaluate the Efficacy and Safety of PEP005 Gel, 0.015% in Patients with Actinic Keratosis ON the Head (Face or Scalp)
8/2009 - 12/2010	A 12 Month, Long Term Follow-up Study of Patients with Actinic Keratosis on the Head (face or Scalp) who have Completed the Day 57 in Studies PEP005-016 or PEP005-025

reel 21 MAY 2020

9/2009 - 07/2011	Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in patient with severe recalcitrant nodular acne
08/2010 - 12/2011	Phase III, A Double-Blind, Vehicle Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients with Moderate to Severe Plaque Psoriasis
09/2010 - 01/2012	Phase II, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris with Nodules
10-2010 - 07/2011	Phase III, A National, Multi-center, Prospective, Randomized, Double-Blind, 4-arm, Parallel Group, 8-week Study in Subjects with Psoriasis Vulgaris on the Non-Scalp Regions of the Body (trunk or limbs)
10-2010 - 07/2011	Phase III, A Randomized, Controlled Evaluation of the Safety and Efficacy of a Topical Treatment for Moderate- Severe Facial Acne Vulgaris
03/2011 - 01/2012	A Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream 3.75% And Zyclara (Imiquimod) Cream 3.75% In Subjects with Actinic Keratoses
06/2011 - 02/2012	A Multicenter, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% to Epiduo and Both Active Treatments to Placebo in the Treatment of Mild to severe Acne Vulgaris
09/2011 - 04/2012	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Study Comparing Metronidazole Topical Gel 1% to Metrogel 1% in the Treatment of Moderate to Severe Rosacea
12/2011 - 07/2012	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Rosacea-Specific Inflammatory Biochemical markers in the Skin of Adults with Papulopustular Rosacea Treated with Daily Doxycycline 40 mg (30 mg Immediate Release/10mg Delayed Release) capsules
12/2011 - 12/2012	A Phase II Study of Photodynamic Therapy with Levulun Topical Solution+ BLU light vs. Levulun Topical Solution Vehicle + BLU Light Using Spot and Broad Area Application and Incubation Times of 1,2, and 3 Hours for the Treatment of Multiple Actinic Keratoses on the Face and Scalp
12/2011 - 08/2012	An Evaluation of the Burden of Illness Among Adults in the United States with Moderate to Severe Plaque Psoriasis
03/2012 - 09/2013	Phase 3 Randomized, Double-Blind, 12- week, Vehicle controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40- week investigator blinded extension comparing the long- term safety of CD5024 1% cream versus azelaic acid 15% gel
03/2012 - 11/2013	A Sequential Treatment Regimen of Cryotherapy and Picato (Ingenol Mebutate) gel, 0.015% Field Therapy Compared to cryotherapy alone for the treatment of Actinic Keratoses on the Face and Scalp
03/2012 - 12/2015	A Phase 3B, Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate a "Subject Tailored" Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis-PSTELLAR
04/2012 - 12/2012	A Phase II Study Comparing Treatment with LEO 90100 with Betamethasone Dipropionate in LEO 90100 Vehicle and Calcipotriol in LEO 90100 Vehicle in Subjects with Psoriasis Vulgaris

lead
21 MAY 2016

04/2012 - 12/2012	A Phase II Study Comparing Treatment with LEO 90100 with Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects with Psoriasis Vulgaris
04/2012 - 12/2012	A Randomized, Double-Blind Placebo Controlled, 4-Week trial of IMO-3100 in Patients with Moderate to Severe Plaque Psoriasis
04/2012 - 05/2014	Randomized, Double-Blind, Vehicle-Controlled, Multicenter, parallel-Group Clinical Trials to assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 weeks in Subjects with papulopustular Rosacea
05/2012 - 01/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Naftifine HCL Cream 1% to Naftin Cream 1% in the Treatment of Tinea Pedis
08/2012 - 07/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Vehicle Controlled, Multicenter Study Comparing Imiquimod 3.75% to Zyclara
08/2012 - 06/2014	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose Escalating Study to Evaluate Coretexalone 17a-Propionate Once Daily or Twice Daily in Subjects with Facial Acne Vulgaris.
10/2012 - 05/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac
10/2012 - 07/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Diclofenac Sodium Gel 3% to Solaraze
10/2012 - 2015	A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis
02/2013 - 02/2013	A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris- Braintree
03/2013 - 09/2013	A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005% Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) with Plaque Psoriasis
04/2013 - 04/2014	A Double-Blind, Randomized, Parallel-Group, Vehicle Controlled, Multicenter Study Comparing TOLMAR Azelaic Acid Gel, 15% to Reference Listed Drug in the Treatment of Rosacea
04/2013 - 12/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Diclofenac Sodium Gel 3% to Solaraze
04/2013 - 06/2014	A Double-Blind, Randomized, Parallel Group, Vehicle-Controlled, Multicenter Study Comparing TOLMAR Naftifine HCl cream, 2% to Reference listed Drug in the treatment of Tinea Pedis
05/2013 - 09/2014	A randomized, Vehicle-Controlled, Double-blind, Parallel Group, Multi-center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis
09/2013 - 02/2015	A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-controlled Study to Evaluate the Safety and Efficacy and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference listed Finacea Gel 15% in patients with Moderate Facial Rosacea

*Lead
21 MAY 2015*

09/2013 - 02/2015	A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritus
11/2013 - 02/2015	Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm ² on The Chest in Subjects with Actinic Keratosis
11/2013 - 08/2014	A Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara cream 2.5% in Subjects with Actinic Keratoses
11/2013 - 06/2015	A Randomized, Double-Blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2%/Benzoyl Peroxide 5% gel versus DUAC Gel versus Placebo in the ratio of 2:2:1 respectively in Patients with Acne Vulgaris
12/2013 - 12/2014	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene Lotion 0.05% and the Efficacy of Bethamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis
2013 – 2019	A 64-week, Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Design, Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects with moderate-to-Severe Plaque Psoriasis
2013 – 2019	IIF-MC-RHBA (b): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Sever Plaque Psoriasis
02/2014 - 10/2014	A randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis
02/2014 - 01/2015	A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris
02/2014 - 09/2014	A Randomized, Double-Blind, Multiple Site, Placebo-Controlled, Parallel Design Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo Topical Gel in the Treatment of Acne Vulgaris
04/2014 - 2016	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Chronic Plaque Psoriasis (CHS-0214-04) (RaPsOdy)
05/2014 - 07/2015	A Phase 3 study of photodynamic therapy with Levulan Kerastick Topical solution + Blue light versus topical solution vehicle+ blue light for the treatments of actinic keratoses on the upper extremities
06/2014 - 02/2015	Efficacy and Safety of Oxymetazoline HCl Cream 1.0% for the Treatment of Persistent Erythema Associated with Rosacea
08/2014 - 2016	Twelve Month Follow-up Evaluation of Subjects Participating in Dusa-CP0108 (A Phase 3 Study of Photodynamic Therapy with Levulan® Kerastick® Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
09/2014 - 09/2015	A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab

11/2014 - 2016	A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
11/2014 - 2016	A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
11/2014 - 2020	A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Incorporating Randomized Withdrawal and Retreatment
11/2014 - 2020	A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
2014 – 2015	Safety and efficacy of escalating doses of LEO 43204 applied once daily for two consecutive days on approximately 250 cm ² on trunk and extremities in subjects with actinic keratosis
2014 – 2017	RegiSONIC: A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
2014 – 2017	A Randomized, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg per Day of Sarecycline Compare to Placebo in the Treatment of Acne Vulgaris
02/2015 - 2016	A Phase 2 Study Comparing The Occurrence Of Actinic Keratoses On The Face In High-Risk Individuals After Cryotherapy + Photodynamic Therapy With Levulan® Topical Solution + Blue Light Versus Cryotherapy + Vehicle Topical Solution + Blue Light
02/2015 - 2016	A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Foam 0.05% versus Vehicle Foam in Subjects with Plaque Psoriasis
02/2015 - 2016	A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis
02/2015 - 2017	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating The Efficacy and Safety Of Multiple Dupilumab Dose Regimens Administered As Monotherapy For Maintaining Treatment Response In Patients With Atopic Dermatitis
02/2015 - 2016	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine The Therapeutic Equivalence Of Generic Fluorouracil Cream, 0.5% And Carac® (Fluorouracil) Cream, 0.5% In Subjects With Actinic Keratoses
04/2015 - 2016	A Multicenter, Randomized, Double-Blind, Vehicle controlled, Parallel Group Comparison Study to Determine The Therapeutic Equivalence Of A Generic Ingenol Mebutate Gel, 0.05% And Picato® Gel, 0.05% In Subjects With Actinic Keratosis On The Trunk Or Extremities
05/2015 - 12/2015	A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% Compared to Solaraze 3%, gel in the Treatment of Actinic Keratosis
05/2015 - 12/2015	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia (AGA)

05/2015 - 2016	A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Three Concentrations of Topically Applied BBI-4000 gel in Subjects with Axillary Hyperhidrosis
05/2015 - 12/2015	A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% Compared to Solaraze 3%, gel in the Treatment of Actinic Keratosis
05/2015 - 12/2015	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia (AGA)
07/2015 - 2016	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 in Subjects with Axillary Hyperhidrosis
07/2015 - 2016	An Open-Label Study Assessing Long-Term Safety of Drm04 In Subjects with Primary Axillary Hyperhidrosis
08/2015 - 2016	A Double-Blind, Randomized, Parallel-Group, Active Control Study to Compare the Efficacy and Safety of CHS-1420 Drug Product Versus Humira® in Subjects With Chronic Plaque Psoriasis
08/2015 - 2016	A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients
2015 – 2018	An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cotexolone 17a (Cb-03-01) Cream, 1% Applied Twice Daily in Subjects with Acne Vulgaris
2015 – 2017	Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm ² on the Chest
2015 – 2017	A double-blind, randomized placebo-controlled study, Evaluating the efficacy and safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
2015 – 2017	A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
2015 – 2017	A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Access the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
2015 - 2017	A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once- Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects with Papulopustular Rosacea with a 4 Week Follow-up Period
2015 – 2017	A Multicenter, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study to Compare the Efficacy and Safety of CD5789 50mg/g Cream Versus Vehicle Cream in Subjects with Acne Vularis
2015 – 2017	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Cortexolone 17a-propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 weeks in Subjects with Facial Acne Vulgaris
2015 – 2017	An Open-Label study of Dupilumab in Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials

Lead 21 MAY 2020

2015 - 2018	An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICIA (isotretinoin) Capsules Administered Without Food in Subjects with Severe Recalcitrant Nodular Acne
2016 - 2017	A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis
2016 - 2016	A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy with Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for Field Treatment of Actinic Keratoses on the Face
2016 - 2016	A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Shampoo in Patients with Mild to Severe Scalp Psoriasis
2016 - 2016	A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy with Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for Field Treatment of Actinic Keratoses on the Face
2016 - 2016	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to Soolantra™ (ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea
2016 - 2017	A Phase 2, Multicenter, Evaluator-Blinded Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IPD-118 Lotion with Tazorac® (tazarotene) Cream, 0.05% in the Treatment of Plaque Psoriasis
2016 - 2017	BI 655066 versus Ustekinumab and placebo comparators in a randomized double-blind trial for Maintenance use in Moderate to severe plaque type psoriasis
2016 - 2018	BI 655066 versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment
2016 - 2018	A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea
2016 - 2017	A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis
2016 - 2017	A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris
2016 - 2017	A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Listed Finacea® (azelaic acid) Foam, 15% in Patients with Moderate Facial Rosacea
2016 - 2017	A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Dose-Ranging, Study to Evaluate the Efficacy and Safety Profile of PF-04965842 In Subjects with Moderate to Severe Atopic Dermatitis

Lead 21 MAY 2016

2016 - 2017	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-Resistant Pruritus Associated with Atopic Dermatitis
2016 - 2017	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of a Generic Ingenol Mebutate Gel, 0.015% And Picato® Gel, 0.015% In Subjects with Actinic Keratosis on The Face or Scalp
2016 - 2017	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 And Diclofenac Sodium Gel, 3% In Subjects with Actinic Keratoses
2016 – 2017	A multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of Trapiditant in treatment-resistant pruritus associated with Atopic Dermatitis
2016 - 2019	A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Plaque Psoriasis
02/2017 - 2024	Clinical Study Protocol M15-997: A multicenter, open Label study to assess the safety and efficacy of Risankizumab for maintenance in moderate to severe Plaque type Psoriasis (LIMMITLESS)
2017 - 2018	A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing TOLMAR Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to Reference Listed Drug in the Treatment of Scalp Psoriasis
2017 – 2018	A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing TOLMAR Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to Reference Listed Drug in the Treatment of Scalp Psoriasis
2017 - 2017	A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 5%, 10% and 15% Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects with Axillary Hyperhidrosis
2017 - 2018	A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
2017 - 2018	A phase 3, Multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO 1959 (Guselkumab) and secukinmab for the treatment of Moderate to Severe Plaque-Type Psoriasis
2017 - 2018	A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1 % Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults with Atopic Dermatitis
2017 - 2018	A Multicenter study of psorx lotion in subjects with moderate plaque psoriasis
2017 - 2018	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 versus Vehicle in Subjects 12 years of age or older with Cutaneous Common Warts
2017 - 2018	A Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied Once A Week in Subjects with Common Warts

Recd 21 MAY 2020

2017 - 2018	A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 weeks in the Treatment of Moderate - to - Severe Acne Vulgaris
2017 - 2018	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥ 12 To < 18 Years of Age, With Moderate-To-Severe Atopic Dermatitis
2017 - 2018	A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison study to evaluate the safety and efficacy of UHE-101 cream 1% when applied twice daily for 12 weeks in subjects with facial acne vulgaris.
2017 - 2018	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib Ointment) in Subjects with Pruritus Associated with Psoriasis Vulgaris
2017 - 2018	A Randomized, Multicenter, Double-blind, Vehicle controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11)
2017 - 2018	A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients with Plaque Psoriasis
2017 - 2019	A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis on the Face or Scalp
2017 - 2019	A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of The Efficacy and Safety of Apremilast (Cc-10004) In Subjects with Moderate to Severe Plaque Psoriasis of The Scalp
04/2018 - 2020	An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects with Atopic Dermatitis
04/2018 - 2020	Tralokinumab in combination with topical corticosteroids for moderate-to-severe atopic dermatitis ECZTRA 3 (Eczema Tralokinumab trial no. 3)
08/2018 - 2020	A Randomized, Double-Blind, Placebo Controlled, Efficacy Study of The Neurokinin-1 Receptor Antagonist Vly-686 In Patients With Atopic Dermatitis
08/2018 - 2020	A Phase 3 Randomized Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of Pf-04965842 In Subjects Aged 12 Years and Over, With Moderate to Severe Atopic Dermatitis with The Option of Rescue Treatment in Flaring Subjects
08/2018 - 2023	A Phase 3 Randomized, Double-Blind, Multi-Center, Long-Term Extension Study Investigating the Efficacy and Safety of Pf-04965842, With or Without Topical Medications, Administered to Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis
09/2018 - 2020	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa
10/2018 - 2020	A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis

Luca 21 MAY 2020

10/2018 - 2020	A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis.
10/2018 -2022	A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis.
2018 - 2018	A Double-Blind, Randomized, Placebo-Controlled Exploratory Study to Assess the Efficacy and Safety of Te-5214 In the Treatment of Subjects with Moderate to Severe Palmar Hyperhidrosis
2018 - 2018	A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and/or Multiple Intravenous and/or Subcutaneous Doses of PF-06817024 in Healthy Subjects Who May Be Mildly Atopic, Subjects with Chronic Rhinosinusitis with Nasal Polyps, and Subjects With Moderate to Severe Atopic Dermatitis
2018 - 2019	An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab In Patients Greater Than or Equal To 6 Months to Less Than 18 Years of Age with Atopic Dermatitis
2018 - 2019	A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study of Gbr 830 In Adult Subjects with Moderate to Severe Atopic Dermatitis
2018 - 2019	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab In Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis
2018 - 2019	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Efficacy, Safety, Tolerability, And Pharmacokinetics of Asn002 In Subjects with Moderate to Severe Atopic Dermatitis
2018 - 2019	A Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects with Actinic Keratosis
2018 - 2019	A Multicenter, Randomized, Double-Blind, Placebo- Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
2018 - 2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects with Acne Vulgaris.
2018 - 2019	A Double-Blind, Randomized, Multicenter, Vehicle Controlled, Parallel Group Comparison Study to Determine the Efficacy and Safety of Halobetasol Propionate Spray, 0.05% Versus Vehicle Spray in Subjects with Plaque Psoriasis Receiving Up to Four Weeks of Twice Daily Treatment
2018 - 2019	A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects with Common Warts (Verruca Vulgaris)
2018 - 2019	An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)
2018 - 2019	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

leach 21 MAY 2020

2018 - 2019	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
2018 – 2021	A randomized, double-blind, placebo-controlled, parallel-group, multiple-site clinical study to evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream 1% (taro Pharmaceuticals) to the market product ELIDEL (pimecrolimus) Cream 1% (Valeant Pharmaceuticals) in the treatment to mild to moderate Atopic Dermatitis
08/2018 - 2025	A Prospective Observational Study of Adult Patients Receiving Dupixent For Atopic Dermatitis
1/2019- 2020	A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
3/2019-2023	An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clinical trials
4/2019- 2020	Phase IIa, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety, tolerability and efficacy of treatment with BI 655130 in adult patients with moderate to severe atopic dermatitis
6/2019-2020	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis
6/2019-2021	A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis
6/2019- 2020	A Randomized Parallel-Group Study to Evaluate the Efficacy and Tolerability of Two Dosing Regimens of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
6/2019- 2021	A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults
6/2019-2021	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus
6/2019-2021	A Phase 3 randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center study investigating the efficacy and safety of pf-04965842 and dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis
7/2019- 2020	A Phase 2, Double Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts (EGW)
8/2019-2021	A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis
10/2019- 2021	A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
10/2019- 2021	A Randomized, Double-Blind, Placebo-Controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients with Atopic Dermatitis

Recd 21 MAY 2020

11/2019-2022	A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
11/2019-2021	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis, who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment
12/2019- 2021	A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis
12/2019- 2021	A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis
2019-2023	A multicenter, open-label study to assess the long-term safety, tolerability, and efficacy of Bimekizumab in adult subjects with moderate to severe Chronic Plaque Psoriasis
2019-2019	A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Urea Cream, 40% applied twice-daily for 6 weeks in subjects with Ichthyosis Vulgaris
2019-2019	A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of Glycopyrronium Cloth, 2.4% in Patients with Palmar Hyperhidrosis
2019-2019	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Proof of Concept Comparison Study of the Safety and Efficacy of DUR-928 Topical Solution with Occlusion in Subjects with Mild to Moderate Plaque Psoriasis
2019-2019	A Prospective, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of a Combination of 3% Minocycline and 0.3% Adapalene Topical Foam Formulation for the Treatment of Moderate-to-Severe Acne (Study FX2016-40)
2019-2019	A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and VehicleGel Once Daily in the Treatment of Molluscum Contagiosum
2019-2019	An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects ages 2 to 17 years with atopic dermatitis
2019-2019	Phase 2 POC study of the safety and efficacy of ARQ-151 cream 0.05% and 0.15% administered QD in adolescent and adult subjects with atopic dermatitis
2019 – 2021	A long-term, open-label, extension study to evaluate the safety and efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults
2019 - 2025	An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
1/2020 - 2021	A phase 2a, randomized, double-blind, placebo- controlled, parallel group, multi-center study to investigate the mechanism of action of pf-04965842 monotherapy in adult participants with moderate-to-severe atopic dermatitis

2/2020 - 2021	A Randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab when used in combination with topical corticosteroid treatment in patients with moderate- to-severe atopic dermatitis
2/2020 - 2021	A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults with Scalp and Body Psoriasis
2/2020 - 2020	A double-blind, randomized, placebo-controlled study to assess the efficacy and safety of AT-5214 in the treatment of subjects with moderate to severe Palmar Hyperhidrosis
2/2020 - 2021	An Open Label, Phase I, Maximal Usage Pharmacokinetics and Safety Study of ARQ-151 Cream 0.3% Administered QD in Adolescent and Adult Subjects with Chronic Plaque Psoriasis
3/2020 - 2021	A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable
4/2020 - 2021	A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients with Non-Gorlin High Frequency BCC
4/2020 - 2022	A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa
4/2020 - 2021	A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults with a History of Atopic Dermatitis
2020 - 2021	A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults with a History of Atopic Dermatitis
2020 – 2022	An open label extension study to assess the long-term safety of treatment with BI 655130 administered subcutaneously in adult patients with moderate to severe atopic dermatitis
2020 – 2021	A randomized, double-blind, placebo-controlled, multicenter, 16-week trial to evaluate the Efficacy and Safety of FB-401 in children, adolescent, and adult subjects (Ages 2 years and older) with mild to moderate Atopic Dermatitis
2020 – 2021	A randomized, parallel, double-blind, vehicle-controlled, study to evaluate the safety and efficacy of two concentrations of Topic TMB-001 for the treatment of Congenital Ichthyosis
2020 – 2021	A phase 2, multicenter, open-label study of the long-term safety of ARQ-154 Foam 0.3% in subjects with Seborrheic Dermatitis
2020 – 2021	A phase 1 and 2, multiple doses and 12-week, parallel group, double blind, dose ranging, vehicle-controlled, study of the safety and efficacy of ARQ-252 Cream 0.3% in subjects with non-segmental facial vitiligo
2020 – 2021	A phase 2a, Proof of Concept, 24-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 Cream 0.3% in subjects with non-segmental facial vitiligo

leach 21 MAY 2020

2020 – 2021	A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of CTP-543 in Adult patients with moderate to severe Alopecia Areata
2020 – 2021	A phase 3, 16-week, randomized, double-blind, placebo-controlled, parallel-group study to assess the Impact of Lebrikizumab on vaccine responses in adult patients with moderate-to-severe Atopic Dermatitis
2020 – 2021	A Phase 1 and 2, Multiple Dose and 12-Week, Parallel Group, Double Blind, Dose Ranging, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.1% and ARQ-252 Cream 0.3% in Subjects with Chronic Hand Eczema
2020 – 2021	A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of ASN002 in Subjects with Moderate to Severe Atopic Dermatitis
2020 – 2021	A Randomized, Parallel, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis
2020 – 2022	A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302
2020 - 2024	A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in patients with moderate to severe Atopic Dermatitis
2020 - 2026	A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
2021 – 2021	A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
2021 – 2021	A phase 3, 4-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of a Cream Administered Q.D. in subjects with Atopic Dermatitis
2021 – 2021	A Phase 2a, Randomized, Double Blind, Vehicle Controlled, Parallel Group Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-07038124 Ointment for 6 weeks in Participants with Mild to Moderate Atopic Dermatitis or Plaque Psoriasis
2021 - 2022	A Phase 3, 8-week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered Q.D. in Subjects with Scalp and Body Psoriasis
2021 – 2022	A Phase 3, 8-week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 FOAM 0.3% Administered Q.D. in subjects with Seborrheic Dermatitis
2021 - 2023	A Study to Evaluate Maintenance of Hair Regrowth Following Dose Reduction of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
2021 - 2023	A Phase 3 efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults
2021 - 2022	A phase 2a/2b, Multicenter, Randomize, Placebo and Active Comparator-controlled, double-blind, dose-ranging, study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the treatment of subjects with moderate to severe Hidradenitis Suppurativa

Lead Jimmy

2021 - 2024	A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines
2021 - 2022	A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects with Notalgia Paresthetica
2021 - 2022	A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
2021 - 2022	Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study: A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
2021 - 2024	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
2021 - 2024	A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis
2021 - 2024	A Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis
2021 - 2025	Inflammatory Skin Disease Treatment Identification Study (IDENTITY)
2022 - 2024	A Phase 2 Dose-finding Study to Evaluate the Efficacy, Safety, and Immunogenicity of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
2022 - 2022	A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm ² on the Face or Balding Scalp in Adult Patients with Actinic Keratosis
2022 - 2023	A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis
2022 - 2023	A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks
2022 - 2024	A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety and Tolerability of AMG 451 in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
2022 - 2022	A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of an Oral Biologic Therapy for Treatment of Moderate to Severe Plaque Psoriasis
2022 - 2022	Open-label 12-week longitudinal exploratory study to assess reliability/feasibility of using Emerald touchless sensor for scratching and sleep quantification in a subset of PEDISTAD patients
2022 - 2023	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnlimab (ANB030) in the Treatment of Subjects with Moderate to Severe Alopecia Areata

lead 21 MAY 2020

2022 – 2023	A Randomized, Vehicle-Controlled, Safety and Efficacy Study of EVO101 in Adult Subjects with Atopic Dermatitis
2022 – 2023	A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
2022 – 2023	A Phase 3b, Multicenter, Randomized, Double-blind, Interventional Treatment Study in Skin of Color Participants with Moderate to Severe Plaque Psoriasis or Moderate to Severe Scalp Psoriasis
2022 – 2023	A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa
2022 – 2023	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, MultiCenter Study to Assess the Efficacy and Safety of Difamilast Ointment 1% in Children, Adolescents, and Adults with Mild to Moderate Atopic Dermatitis
2022 – 2024	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderate to Severe Psoriasis
2022 – 2023	PSoSA (PSoriasis Special Areas) - a US-based, SingleArm, Prospective, Multicenter, Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab
2022 – 2023	A Phase 2A, Open Label, Proof-of-Concept Trial of Daxdilimab for the Treatment of Moderate-to-Severe Alopecia Areata
2022 – 2024	A Two-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate-to-Severe Pruritus in Adult Subjects with Atopic Dermatitis
2022 – 2024	A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof of Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis
2022 - 2024	The ASCEND Trial: A Multicenter, Double Blinded Vehicle Controlled Study of TMB-001, a Proprietary Isotretinoin Ointment, in the Treatment of RXLI (X-linked) or ARCI (Lamellar) Ichthyosis; Preceded by a Voluntary Maximal Use Study; Both Studies in Subjects 6 Years of Age and Above
2022 – 2024	A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis
2022 – 2024	A MultiCenter, Open-Label Study to Assess the Long-Term Safety of Difamilast Ointment 1% in the Treatment of Children, Adolescents, and Adults with Mild to Moderate Atopic Dermatitis
2022 - 2025	Phase 3, 52-week Treat-through Study Evaluating AMG 451 Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)
2023 – 2023	A Phase 4, open-label study to investigate the efficacy and safety of VTAMA® (tapinarof) cream, 1 % in the treatment of plaque psoriasis in intertriginous areas
2023 – 2023	A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Padagis Israel Pharmaceuticals, Ltd.'s Roflumilast Cream 0.3% to Arcutis Biotherapeutics, Inc's Zoryve (Roflumilast Cream 0.3%) and Both Active Treatments to a Vehicle Control in the Treatment of Chronic Plaque Psoriasis

2023 – 2023	A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia
2023 – 2024	A Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis
2023 – 2024	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous Urticaria
2023 – 2024	A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects With Notalgia Paresthetica
2023 – 2024	A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
2023 – 2024	Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects with Atopic Dermatitis
2023 – 2025	A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris
2023 – 2025	An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
2023 – 2025	A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata
2023 – 2025	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
2023 – 2026	A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis
2024 – 2024	A Double-blind, Randomized, Placebo-controlled, 3-Part Study Investigating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of BFB759 in Healthy Participants, Patients with Moderate-Severe Atopic Dermatitis, and Patients with Moderate-Severe Hidradenitis Suppurativa
2024 – 2025	A clinical trial to evaluate the efficacy and safety of tralokinumab in adults subjects with atopic dermatitis and moderate-to-severe atopic hand eczema who are candidates for systemic therapy
2024 – 2025	A Phase 3 Study of Tolerability, Safety, and Efficacy of DMT310 in Patients with Acne Vulgaris
2024 – 2025	Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
2024 – 2025	A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Non-Pustular Palmoplantar and Genital Psoriasis (Psoriatyk Special Sites)

2024 – 2025	A Phase 2a Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants with Moderate to Severe Atopic Dermatitis
2024 – 2025	An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria
2024 – 2026	A 12-week, Randomized, Double-Blind, Phase 4 Study Evaluating the Effect of AIRSUPRA Compared to Albuterol Administered As Needed on Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization in Adults with Mild Asthma (DARWIN)
2024 – 2026	A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
2025 – 2025	Safety and Effectiveness of CGB-500 Topical Ointment with 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: A Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial
2025 – 2025	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2025 – 2026	Open-label phase I study to evaluate the pharmacokinetics of 5-aminolevulinic acid and protoporphyrin IX in human plasma under maximal use conditions after topical application of 3 tubes of BF-200 ALA to a treatment field of 240 cm ² for photodynamic therapy (PDT) in subjects suffering from actinic keratosis in the periphery

CURRENT TRIALS:

09/2008 - Present	Phase IV Study of Remicade Safety (PSOLAR)
2018 - Present	Prospective, observational, longitudinal study in pediatric patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable.
2021 - Present	A Phase 3, Open-label, Parallel Group, Multicenter, Extension Study Evaluating The Long-term Treatment of Bimekizumab In Study Participants With Moderate To Severe Hidradentis Suppurativa
2023 – Present	A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerability of remibrutinib (LOU064) in adult chronic spontaneous urticaria patients who completed the preceding remibrutinib Phase 3 studies
2023 – Present	A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)
2023 – Present	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate-to-Severe Plaque Psoriasis with Randomized Withdrawl and Retreatment
2023 – Present	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and safety of an Oral compound for the Treatment of Participants with Plaque Psoriasis with At Least Moderate Special Area Involvement

2024 – Present	A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2024 – Present	A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1- antihistamines
2024 – Present	A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa
2024 – Present	A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
2024 – Present	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU2)
2024 – Present	Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered with Tirzepatide in Adult Participants with Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)
2024 – Present	A randomized, double-blind, vehicle-controlled, multicenter Phase III study to evaluate the safety, tolerability, and efficacy of BF-200 ALA (Ameluz®) in the field-directed treatment of actinic keratosis on the extremities and neck/trunk with photodynamic therapy (PDT) using the BF-RhodoLED® XL or BF-RhodoLED® lamp.
2024 – Present	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa – The CEDAR Study
2025 – Present	A Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of 3 subcutaneous dose regimens of lunsekimig (SAR443765) in adult participants with moderate-to-severe atopic dermatitis
2025 – Present	A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects with Moderate to Severe Genital Psoriasis
2025 – Present	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Male Subjects with Androgenetic Alopecia
2025 – Present	A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria
2025 – Present	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, MultiPart, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-1310 in Healthy Adult Volunteers, Patients with Atopic Dermatitis, and Patients with Chronic Pruritus

Lucas 21 MAY 2020

2025 – Present	A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants with Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight in Clinical Practice
2025 – Present	A Phase 2b, Multicenter, Randomized Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Moderate to Severe Atopic Dermatitis
2025 – Present	An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001 (ONWARD3)
2025 – Present	A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Hidradenitis Suppurativa
2025 – Present	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Efficacy and Safety of VDPHL01 in Female Subjects with Androgenetic Alopecia
2025 – Present	Topical Ruxolitinib Evaluation in Hidradenitis Suppurativa (TRuE-HS2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
2025 – Present	A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria.
2025 – Present	A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025 – Present	A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Atopic Dermatitis (COMPASS 2-AD)
2025 – Present	Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety of Reformulated Levulan Kerastick plus Photodynamic Therapy (PDT) for Field-Directed Treatment in Patients with Actinic Keratosis (AK) of Face and (Bald) Scalp
2025 – Present	Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety of Reformulated Levulan Kerastick plus Photodynamic Therapy (PDT) for Field-Directed Treatment in Patients with Actinic Keratosis (AK) of Upper Extremities
2025 – Present	A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to < 24 Months with Atopic Dermatitis
2025 – Present	A Multicenter, Randomized, Double-Blinded, Placebo Controlled, Dose-Range Finding Study of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
2025 – Present	COVE-2: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102) in Subjects with Common Warts (Verruca Vulgaris)
2026 – Present	A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa (COMPASS 2 - HS)

2026 – Present	A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
2026 – Present	COVE-4: A Phase 3, Open-Label, Long-Term Follow-Up Study to Evaluate the Safety and Efficacy of YCANTH (VP-102/TO-208) in Subjects with Common Warts (Verruca Vulgaris)
2026 – Present	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-week Study Evaluating the Safety and Efficacy of Ritlecitinib (PF-06651600) in Adults with Moderate to Severe Hidradenitis Suppurativa

I have signed my CV to acknowledge that it is accurate, complete, and current, as of the date of signing.

Signed:  Date: 21 MAY 2020